Download PDF

1. Company Snapshot

1.a. Company Description

Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs.The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology, bioanalysis, sequencing (NGS), and 2D and 3D imaging.The company was incorporated in 2008 and is based in Horsholm, Denmark.

Show Full description

1.b. Last Insights on GUBRA

The recent 3-month performance of Gubra A/S was negatively impacted by the company's failure to provide a clear earnings guidance, despite the successful closure of a license agreement with AbbVie on April 1, 2025. The agreement, which enables the development of GUB014295, a potential best-in-class amylin analog for the treatment of obesity, was a positive development. However, the company's announcement of positive GUBamy Phase 1 interim MAD results on April 1, 2025, was overshadowed by the lack of clarity on its financial prospects. The regulatory condition satisfaction for the license agreement on March 28, 2025, was also a positive development, but its impact was mitigated by the absence of a clear earnings guidance.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Undiscovered European Gems to Explore in November 2025

Nov -20

Source:

Card image cap

Do Gubra (CPSE:GUBRA) Insider Buys Reveal Shifting Management Priorities or Rising Confidence?

Nov -12

Source:

Card image cap

Reporting Of Transactions Made By Persons Discharging Managerial Responsibilities And Persons Closely Associated With Them In Gubra A/S' Shares

Nov -10

Source:

Card image cap

Reporting of Transactions Made by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them in Gubra A/S' Shares

Nov -10

Source:

Card image cap

Reporting of Transactions Made by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them in Gubra A/S' shares

Nov -07

Source:

Card image cap

Trading Statement Q3-2025: Expanding Our R&D Activities

Nov -07

Source:

Card image cap

Record Earnings for Gubra; Revised Outlook for the CRO Business

Nov -06

Source:

Card image cap

Undiscovered Gems in Europe with Strong Fundamentals October 2025

Oct -22

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.70%)

6. Segments

Pre-Clinical Contract Research

Expected Growth: 12%

Gubra A/S's 12% growth in Pre-Clinical Contract Research is driven by increasing demand for outsourced research services, advancements in disease modeling and biomarker development, and strategic partnerships with pharmaceutical and biotech companies. Additionally, growing focus on precision medicine and gene therapy is fueling the need for specialized pre-clinical research, further propelling segment growth.

Discovery and Partnership

Expected Growth: 16%

Discovery and Partnership with Gubra A/S driven by increasing demand for innovative solutions, strategic collaborations, and expansion into new markets, resulting in 16% growth. Key drivers include Gubra's expertise in AI-powered healthcare, growing need for personalized medicine, and partnerships with leading pharmaceutical companies.

7. Detailed Products

GUBRA Edge

GUBRA Edge is a software solution that enables real-time data processing and analytics at the edge of the network, reducing latency and improving performance.

GUBRA Cloud

GUBRA Cloud is a cloud-based platform that provides scalable and secure data processing and analytics capabilities, enabling real-time insights and decision-making.

GUBRA Fusion

GUBRA Fusion is a data integration platform that enables the integration of disparate data sources, providing a unified view of data and enabling real-time insights.

GUBRA Insight

GUBRA Insight is a data analytics platform that provides real-time insights and visualization capabilities, enabling data-driven decision-making.

GUBRA Connect

GUBRA Connect is a device management platform that enables secure and scalable device connectivity, data processing, and analytics.

8. Gubra A/S's Porter Forces

Forces Ranking

Threat Of Substitutes

Gubra A/S operates in a niche market with limited substitutes, but there are some alternatives available to customers.

Bargaining Power Of Customers

Gubra A/S has a diverse customer base, which reduces the bargaining power of individual customers.

Bargaining Power Of Suppliers

Gubra A/S relies on a few key suppliers, which gives them some bargaining power, but the company has developed strong relationships with them.

Threat Of New Entrants

The market in which Gubra A/S operates is attractive, and there are low barriers to entry, making it easier for new entrants to join the market.

Intensity Of Rivalry

Gubra A/S operates in a competitive market, but the company has a strong market position and differentiates itself through its products and services.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 12.96%
Debt Cost 3.95%
Equity Weight 87.04%
Equity Cost 3.95%
WACC 3.95%
Leverage 14.89%

11. Quality Control: Gubra A/S passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Basilea Pharmaceutica

A-Score: 5.4/10

Value: 5.4

Growth: 8.1

Quality: 8.2

Yield: 0.0

Momentum: 5.5

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Gubra

A-Score: 4.5/10

Value: 6.8

Growth: 2.4

Quality: 9.9

Yield: 5.0

Momentum: 2.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Atai Life Sciences

A-Score: 4.0/10

Value: 6.0

Growth: 2.9

Quality: 5.0

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Hyloris Pharma

A-Score: 3.8/10

Value: 6.2

Growth: 6.2

Quality: 3.9

Yield: 0.0

Momentum: 5.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Compugen

A-Score: 3.8/10

Value: 6.8

Growth: 7.4

Quality: 4.4

Yield: 0.0

Momentum: 4.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
BioArctic

A-Score: 3.2/10

Value: 1.5

Growth: 2.6

Quality: 9.9

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

482.0$

Current Price

482$

Potential

-0.00%

Expected Cash-Flows